Pregnancies conceived using assisted reproductive technologies (ART) have low levels of pregnancy-associated plasma protein-A (PAPP-A) leading to a high rate of false-positive results in first trimester screening for Down syndrome

Human Reproduction

Volumn 24, Issue 6, 2009, Pages 1330-1338

  Amor, D J ^a,b,c   Xu, J X ^a,b   Halliday, J L ^a,b   Francis, I ^a   Healy, D L ^d,e   Breheny, S ^d,e   Baker, H W G ^b,c   Jaques, A M ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MELBOURNE IVF   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e MONASH IVF   (Australia)

Author keywords

ART; Hormonal stimulation; PAPP A; Pregnancy complications; Pregnancy screening

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADOLESCENT; ADULT; AMNIOCENTESIS; ARTICLE; CHORION VILLUS SAMPLING; CONTROLLED STUDY; DOWN SYNDROME; EMBRYO TRANSFER; FALSE POSITIVE RESULT; FEMALE; FETUS ECHOGRAPHY; FETUS HEART; FIRST TRIMESTER PREGNANCY; HUMAN; INFERTILITY THERAPY; NUCHAL TRANSLUCENCY MEASUREMENT;

EID: 66249103658     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dep046     Document Type: Article

References (45)

1. Anckaert E, Schiettecatte J, Sleurs E, Devroey P, Smitz J. First trimester screening for Down's syndrome after assisted reproductive technology: non-male factor infertility is associated with elevated free beta-human chorionic gonadotropin levels at 10-14 weeks of gestation. Fertil Steril 2008;90:1206-1210.
2. Barkai G, Goldman B, Ries L, Chaki R, Dor J, Cuckle H. Down's syndrome screening marker levels following assisted reproduction. Prenat Diagn 1996;16:1111-1114.
3. Barrett SL, Bower C, Hadlow NC. Use of the combined first-trimester screen result and low PAPP-A to predict risk of adverse fetal outcomes. Prenat Diagn 2008;28:28-35.
4. Bellver J, Lara C, Soares SR, Ramirez A, Pellicer A, Remohi J, Serra V. First trimester biochemical screening for Down's syndrome in singleton pregnancies conceived by assisted reproduction. Hum Reprod 2005; 20:2623-2627.
5. Belva F, Henriet S, Van den Abbeel E, Camus M, Devroey P, Van der Elst J, Liebaers I, Haentjens P, Bonduelle M. Neonatal outcome of 937 children born after transfer of cryopreserved embryos obtained by ICSI and IVF and comparison with outcome data of fresh ICSI and IVF cycles. Hum Reprod 2008;23:2227-2238.
6. Bersinger NA, Wunder D, Vanderlick F, Chanson A, Pescia G, Janecek P, Boillat E, Birkhauser MH. Maternal serum levels of placental proteins after in vitro fertilisation and their implications for prenatal screening. Prenat Diagn 2004;24:471-477.
7. Conover CA, Bale LK, Overgaard MT, Johnstone EW, Laursen UH, Fuchtbauer EM, Oxvig C, van Deursen J. Metalloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor during fetal development. Development 2004;131:1187-1194.
8. Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, Comstock CH, Hankins G, Berkowitz RL, Merkatz I, Craigo SD et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol 2004;191:1446-1451.
9. Frishman GN, CanickJA, HoganJW, Hackett RJ, Kellner LH, Saller DN Jr. Serum triple-marker screening in in vitro fertilization and naturally conceived pregnancies. Obstet Gynecol 1997;90:98-101.
10. Ghisoni L, Ferrazzi E, Castagna C, Levi Setti PE, Masini AC, Pigni A. Prenatal diagnosis after ART success: the role of early combined screening tests in counselling pregnant patients. Placenta 2003; 24(Suppl B):S99-S103.
11. Giudice LC, Conover CA, Bale L, Faessen GH, Ilg K, Sun I, Imani B, Suen LF, Irwin JC, Christiansen M et al. Identification and regulation of the IGFBP-4 protease and its physiological inhibitor in human trophoblasts and endometrial stroma: evidence for paracrine regulation of IGF-II bioavailability in the placental bed during human implantation. J Clin Endocrinol Metab 2002;87:2359-2366.
12. Gjerris AC, Loft A, Pinborg A, Tabor A, Christiansen M. First-trimester screening in pregnancies conceived by assisted reproductive technology: significance of gestational dating by oocyte retrieval or sonographic measurement of crown-rump length. Ultrasound Obstet Gynecol 2008;32:612-617.
13. Guibourdenche J, Frendo JL, Pidoux G, Bertin G, Luton D, Muller F, Porquet D, Evain-Brion D. Expression of pregnancy-associated plasma protein-A (PAPP-A) during human villous trophoblast differentiation in vitro. Placenta 2003;24:532-539.
14. Halliday J. Outcomes of IVF conceptions: are they different? Best Pract Res Clin Obstet Gynaecol 2007;21:67-81.
15. Heijnen EM, Eijkemans MJ, De Klerk C, Polinder S, Beckers NG, Klinkert ER, Broekmans FJ, Passchier J, Te Velde ER, Macklon NS et al. A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial. Lancet 2007;369:743-749.
16. Helmerhorst FM, Perquin DA, Donker D, Keirse MJ. Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies. BMJ 2004;328:261.
17. Hui PW, Lam YH, Tang MH, Ng EH, Yeung WS, Ho PC. Maternal serum pregnancy-associated plasma protein-A and free beta-human chorionic gonadotrophin in pregnancies conceived with fresh and frozen-thawed embryos from in vitro fertilization and intracytoplasmic sperm injection. Prenat Diagn 2005a;25:390-393.
18. Hui PW, Tang MH, Lam YH, Yeung WS, Ng EH, Ho PC. Nuchal translucency in pregnancies conceived after assisted reproduction technology. Ultrasound Obstet Gynecol 2005b;25:234-238.
19. JaquesAM, Collins VR, Haynes K, Sheffield LJ, Francis I, Forbes R, HallidayJL. Using record linkage and manual follow-up to evaluate the Victorian maternal serum screening quadruple test for Down's syndrome, trisomy 18 and neural tube defects. JMed Screen 2006;13:8-13.
20. Jaques AM, Halliday JL, Francis I, Bonacquisto L, Forbes R, Cronin A, Sheffield LJ. Follow up and evaluation of the Victorian first-trimester combined screening programme for Down syndrome and trisomy 18. BJOG 2007;114:812-818.
21. Lambert-Messerlian G, Dugoff L, Vidaver J, Canick JA, Malone FD, Ball RH, Comstock CH, Nyberg DA, Saade G, Eddleman K et al. First- and second-trimester Down syndrome screening markers in pregnancies achieved through assisted reproductive technologies (ART): a FASTER trial study. Prenat Diagn 2006;26:672-678.
22. Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ, Hays LG, Yates JR III, Conover CA. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci U S A 1999;96:3149-3153.
23. Liao AW, Heath V, Kametas N, Spencer K, Nicolaides KH. First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction. Hum Reprod 2001;16:1501-1504.
24. Lin TM, Galbert SP, Kiefer D, Spellacy WN, Gall S. Characterization of four human pregnancy-associated plasma proteins. Am J Obstet Gynecol 1974;118:223-236.
25. Maman E, Lunenfeld E, Levy A, Vardi H, Potashnik G. Obstetric outcome of singleton pregnancies conceived by in vitro fertilization and ovulation induction compared with those conceived spontaneously. Fertil Steril 1998;70:240-245.
26. Maymon R, Shulman A. Serial first- and second-trimester Down's syndrome screening tests among IVF-versus naturally-conceived singletons. Hum Reprod 2002; 17:1081 - 1085.
27. Maymon R, Shulman A. Integrated first- and second-trimester Down syndrome screening test among unaffected IVF pregnancies. Prenat Diagn 2004;24:125-129.
28. Nicolaides KH. The 11-13+ 6 Weeks Scan. London: Fetal Medicine Foundation, 2004.
29. Niemimaa M, Heinonen S, Seppala M, Hippelainen M, Martikainen H, Ryynanen M. First-trimester screening for Down's syndrome in in vitro fertilization pregnancies. Fertil Steril 2001;76:1282- 1283.
30. Ong CY, Liao AW, Spencer K, Munim S, Nicolaides KH. First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG 2000;107:1265-1270.
31. Orlandi F, Rossi C, Allegra A, Krantz D, Hallahan T, Orlandi E, Macri J. First trimester screening with free beta-hCG, PAPP-A and nuchal translucency in pregnancies conceived with assisted reproduction. Prenat Diagn 2002;22:718-721.
32. Raty R, Virtanen A, Koskinen P, Anttila L, Forsstrom J, Laitinen P, Morsky P, Tiitinen A, Ekblad U. Serum free beta-HCG and alpha-fetoprotein levels in IVF, ICSI and frozen embryo transfer pregnancies in maternal mid-trimester serum screening for Down's syndrome. Hum Reprod 2002;17:481-484.
33. Ribbert LS, Kornman LH, De Wolf BT, Simons AH, Jansen CA, Beekhuis JR, Mantingh A. Maternal serum screening for fetal Down syndrome in IVF pregnancies. Prenat Diagn 1996;16:35-38.
34. Schieve LA, Meikle SF, Ferre C, Peterson HB, Jeng G, Wilcox LS. Low and very low birth weight in infants conceived with use of assisted reproductive technology. N Engl J Med 2002;346:731 -737.
35. Shevell T, Malone FD, Vidaver J, Porter TF, Luthy DA, Comstock CH, Hankins GD, Eddleman K, Dolan S, Dugoff L et al. Assisted reproductive technology and pregnancy outcome. Obstet Gynecol 2005;106:1039- 1045.
36. Shih W, Rushford DD, Bourne H, Garrett C, McBain JC, Healy DL, Baker HW. Factors affecting low birthweight after assisted reproduction technology: difference between transfer of fresh and cryopreserved embryos suggests an adverse effect of oocyte collection. Hum Reprod 2008;23:1644-1653.
37. Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early-pregnancy origins of low birth weight. Nature 2002; 417:916.
38. Smith GCS, Shah I, Crossley JA, Aitken DA, Pell JP, Nelson SM, Cameron AD, Connor MJ, Dobbie R. Pregnancy-associated plasma protein A and alpha-fetoprotein and prediction of adverse perinatal outcome. Obstet Gynecol2006;107:161 -166.
39. Tul N, Novak-Antolic Z. Serum PAPP-A levels at 10-14 weeks of gestation are altered in women after assisted conception. Prenat Diagn 2006; 26:1206-121 1.
40. Wada I, Macnamee MC, Wick K, Bradfield JM, Brinsden PR. Birth characteristics and perinatal outcome of babies conceived from cryopreserved embryos. Hum Reprod 1994;9:543-546.
41. Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T, Haddow JE, Knight GJ, Palomaki GE, Canick JA. Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988;297: 883-887.
42. Wald NJ, White N, Morris JK, Huttly WJ, CanickJA. Serum markers for Down's syndrome in women who have had in vitro fertilisation: implications for antenatal screening. BJOG 1999; 106:1304-1306. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 2003;7:1-77.
43. Wang YA, Sullivan EA, Black D, Dean J, Bryant J, Chapman M. Preterm birth and low birth weight after assisted reproductive technology-related pregnancy in Australia between 1996 and 2000. Fertil Steril 2005;83:1650- 1658.
44. Wang YA, Dean J, Sullivan EA. Assisted Reproduction Technology in Australia and New Zealand 2005. Sydney: AIHW National Perinatal Statistics Unit, 2007.
45. Wojdemann KR, Larsen SO, Shalmi A, Sundberg K, Christiansen M, Tabor A. First trimester screening for Down syndrome and assisted reproduction: no basis for concern. Prenat Diagn 2001;21:563-565.